Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.

Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa ...

Investing.com -- Denali Therapeutics Inc (NASDAQ:DNLI) stock rose 5.7% on Thursday after the company announced a $275 million synthetic royalty funding agreement with Royalty Pharma plc (NASDAQ:RPRX) ...

In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...

Denali Therapeutics and Royalty Pharma entered a $275 million royalty funding agreement based on future sales of tividenofusp alfa.

Denali Therapeutics ( ($DNLI) ) has issued an update. On December 4, 2025, Denali Therapeutics entered into a $275 million synthetic royalty ...

Denali Therapeutics ( ($DNLI) ) just unveiled an announcement. On December 4, 2025, Denali Therapeutics held its Investor Day, updating ...

Denali's validated platform, strategic pipeline, and experienced management present a compelling long-term investment opportunity. Find out why DNLI stock is a Buy.